Miscarriage, Recurrent
Conditions
Brief summary
Recurrent unexplained spontaneous miscarriage (RSM) is defined as three consecutive pregnancy loss prior to 20 weeks from the last menstrual period. 1% to 2% of women experience RSM. Treatment of URSM is a challenging issue. The currently available lines of treatment according to simplicity of use, reliability and degree of invasiveness include corticosteroids, sildenafil citrate, aspirin, heparin and immunoglobulins (besides good antenatal care), but up to now there are no prospective randomized studies, powerful enough, to determine a significant difference between these therapeutic protocols, with any of the above mentioned pharmacological agents. Sildenafil Citrate (Viagra®), a vasodilator, is also described as an anti-inflammatory agent. While improving uterine blood flow in the proliferative phase, NO may have detrimental effects at the level of the endometrium during the implantation window. The NO- mediated release of cytokines such as tumour necrosis factor- from activated natural killer cells has been implicated as a cause of implantation failure. Based on these observations, this study attempts was made to study uterine arteries and sub-endometrial blood flow during the luteal phase in normal fertile women and in patients with Unexplained recurrent miscarriage
Interventions
DRUGSildenafil Citrate
Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period
DRUGFolic Acid
Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally
DRUGPlacebo Oral Tablet
Placebo tablet apparently identical to Respatio(R) 25mg tablets, taken four times daily for 24 days preconceptionally starting first day of previous period
Sponsors
Ain Shams University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Masking description
Patients are randomized to receive either folic acid and sildenafil citrate or folic acid and placebo. Placebo tablets were same size and appearance of the sildenafil citrate tablets.
Intervention model description
Patients will be randomized into two groups: Group (A) folic acid and sildenafil citrate and Group (B) folic acid and placebo. Folic acid (0.5 mg) will be started 3 months before conception in the two groups. Sildenafil citrate (dose: 25 mg; oral tablets, 4 times/day) or placebo will be started preconception for 24 days
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
* Age: 20-35 years. * BMI (20-30) * History of three or more successive unexplained recurrent miscarriage. * Normal uterine cavity by hystrography or hysteroscopy. * No luteal phase defects by progesterone \> 10 ng. * Normal thyroid function (TSH, T3, T4) * Normal lupus anticoagulant measured by activated partial throbmoplastine time (32-43 seconds). * Normal anticardolipin (IgG \< 20 gpl and IgM \< 15 MPL measured by ELISA). * Normal anti thyroid antibodies. * Normal glucouse tolerance test. * Normal parental karyotyping.
Exclusion criteria
* Age\<20 or\>35 year * BMI\<20 or\>30 * Systemic diseases that might affect pregnancy such as diabetes or thyroid disorders or hypertension. * History of consanguinity. * Family history of chromosomal abnormalities (e.g. trisomy 21, trisomy 13, Turner's disease …etc.). * History of autoimmune diseases, eg: systemic lupus. * Congenital anomaly in uterine cavity as bicornate or septate uterus. * Luteal phase defect and corpus luteum insufficiency. * Uterine masses as fibroid or polyps. * Patient with patuoles os. * patient with antiphosphlipid syndrome. * Cigarette smoking and alcohol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Miscarriage rate | 24 gestational weeks | number of spontaneous/missed miscarriages among the participants in both groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Uterine artery resistance index | At 24 gestational weeks | Uterine artery resistance index assessed by uterine artery Doppler study in ongoing pregnancies of both groups |
| Uterine artery pulsatility index | At 24 gestational weeks | Uterine artery pulsatility index assessed by uterine artery Doppler study in ongoing pregnancies of both groups |
Countries
Egypt
Outcome results
None listed